Influence of the acidic beverage cola on the absorption of erlotinib in patients with non-small-cell lung cancer

Journal of Clinical Oncology

Volumn 34, Issue 12, 2016, Pages 1309-1314

  Van Leeuwen, Roelof W F ^a,b   Peric, Robert ^a   Hussaarts, Koen G A M ^a   Kienhuis, Emma ^a   IJzerman, Nikki S ^a   De Bruijn, Peter ^a   Van Der Leest, Cor ^a,c   Codrington, Henk ^d   Kloover, Jeroen S ^e   Van Der Holt, Bronno ^a   Aerts, Joachim G ^a,c   Van Gelder, Teun ^b   Mathijssen, Ron H J ^a  

^a ERASMUS MC CANCER INSTITUTE   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c AMPHIA HOSPITAL   (Netherlands)

^d HAGA HOSPITAL   (Netherlands)

^e CPRLab   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ERLOTINIB; ESOMEPRAZOLE; ANTINEOPLASTIC AGENT; PROTEIN KINASE INHIBITOR; PROTON PUMP INHIBITOR;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; COLA; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; HUMAN; MALE; MONOTHERAPY; NAUSEA; NON SMALL CELL LUNG CANCER; OPEN STUDY; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SKIN TOXICITY; VOMITING; AGED; BIOAVAILABILITY; BLOOD; CARBONATED BEVERAGE; CARCINOMA, NON-SMALL-CELL LUNG; DRUG MONITORING; FOOD DRUG INTERACTION; GASTROINTESTINAL ABSORPTION; LUNG NEOPLASMS; MIDDLE AGED; NETHERLANDS; ORAL DRUG ADMINISTRATION; PATHOLOGY; PH;

ADMINISTRATION, ORAL; ADULT; AGED; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CARBONATED BEVERAGES; CARCINOMA, NON-SMALL-CELL LUNG; CROSS-OVER STUDIES; DRUG MONITORING; ERLOTINIB HYDROCHLORIDE; ESOMEPRAZOLE; FEMALE; FOOD-DRUG INTERACTIONS; GASTROINTESTINAL ABSORPTION; HUMANS; HYDROGEN-ION CONCENTRATION; LUNG NEOPLASMS; MALE; MIDDLE AGED; NETHERLANDS; PROTEIN KINASE INHIBITORS; PROTON PUMP INHIBITORS;

EID: 84963582649     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2015.65.2560     Document Type: Article

References (19)

1. Herbrink M, Nuijen B, Schellens JH, et al: Variability in bioavailability of small molecular tyrosine kinase inhibitors. Cancer Treat Rev 41:412-422, 2015
2. Van Leeuwen RW, Van Gelder T, Mathijssen RH, et al: Drug-drug interactions with tyrosine-kinase inhibitors: A clinical perspective. Lancet Oncol 15: E315-e326, 2014
3. Budha NR, Frymoyer A, Smelick GS, et al: Drug absorption interactions between oral targeted anticancer agents and PPIs: Is pH-dependent solubility the Achilles heel of targeted therapy? Clin Pharmacol Ther 92:203-213, 2012
4. Van Leeuwen RW, Jansman FG, Van Den Bemt PM, et al: Drug-drug interactions in patients treated for cancer: A prospective study on clinical interventions. Ann Oncol 26:992-997, 2015
5. Chu MP, Ghosh S, Chambers CR, et al: Gastric acid suppression is associated with decreased erlotinib efficacy in non-small-cell lung cancer. Clin Lung Cancer 16:33-39, 2015
6. Food and Drug Administration: Food and Drug Administration Product Reviews and Labels. https://www.accessdata.fda.gov/scripts/cder/drugsatfda/
7. Smelick GS, Heffron TP, Chu L, et al: Prevalence of acid-reducing agents (ARA) in cancer populations and ARA drug-drug interaction potential for molecular targeted agents in clinical development. Mol Pharm 10:4055-4062, 2013
8. Jaruratanasirikul S, Kleepkaew A: Influence of an acidic beverage (Coca-Cola) on the absorption of itraconazole. Eur J Clin Pharmacol 52:235-237, 1997
9. Chin TW, Loeb M, Fong IW: Effects of an acidic beverage (Coca-Cola) on absorption of ketoconazole. Antimicrob Agents Chemother 39: 1671-1675, 1995
10. Hunfeld NG, Touw DJ, Mathot RA, et al: A comparison of the acid-inhibitory effects of esomeprazole and pantoprazole in relation to pharmacokinetics and CYP2C19 polymorphism. Aliment Pharmacol Ther 31:150-159, 2010
11. Hunfeld NG, Touw DJ, Mathot RA, et al: A comparison of the acid-inhibitory effects of esomeprazole and rabeprazole in relation to pharmacokinetics and CYP2C19 polymorphism. Aliment Pharmacol Ther 35:810-818, 2012
12. Food and Drug Administration: Guidance for industry: Drug interaction studies-study design, data analysis, implications for dosing, and labeling recommendations. http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093606.htm
13. Massachusetts General Hospital Biostatistics Center: Statistical considerations for a cross-over study where the outcome is a measurement.http://www.hedwig.mgh.harvard.edu/sample-size/js/js-crossover-quant.html
14. STATA: STATA 13 Base Reference Manual. pp 1594-1602
15. Oostendorp RL, Buckle T, Beijnen JH, et al: The effect of P-gp (Mdr1a/1b), BCRP (Bcrp1) and P-gp/BCRP inhibitors on the in vivo absorption, distribution, metabolism and excretion of imatinib. Invest New Drugs 27:31-40, 2009
16. Kloth JS, Binkhorst L, De Wit AS, et al: Relationship Between sunitinib pharmacokinetics and administration time: Preclinical and clinical evidence. Clin Pharmacokinet 54:851-858, 2015
17. Mathijssen RH, Sparreboom A, Verweij J: Determining the optimal dose in the development of anticancer agents. Nat Rev Clin Oncol 11:272-281, 2014
18. Carrillo JA, Benitez J: Clinically significant pharmacokinetic interactions between dietary caffeine and medications. Clin Pharmacokinet 39: 127-153, 2000
19. Food and Drug Administration: Waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a Biopharmaceutics Classification System: Guidance for industry. http://www.fda.gov/Drugs/Guidance-ComplianceRegulatoryInformation/Guidances/default.htm